300357:SZSEZhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Class A Analysis

Zhejiang Wolwo Bio-Pharmaceutical is trading at CNY 24.99, well above its DCF‑derived fair value of roughly CNY 10.2, indicating a significant overvaluation. The company boasts exceptional profitability metrics – a gross margin of 95.3% and operating margin of 50.7% – and a robust revenue growth rate of 22.6% YoY, supported by strong cash generation (operating cash flow of CNY 389 M) and a modest debt profile (debt‑to‑equity 0.71). However, technical signals are mixed: the price sits below the 20‑, 50‑ and 200‑day SMAs, the RSI is at 32.9 (near oversold), and the MACD remains bearish, though volume is trending upward.
Given the high valuation multiples (PE 33.3 vs industry 26.5, PB 4.96) and modest upside from technical momentum, the stock may be better suited for investors with a longer horizon who can tolerate short‑term price pressure while the company continues to leverage its high‑margin product portfolio and low payout ratio (≈30%) to drive growth.